We are beginning to see the limits of targeted therapy and immunotherapy and all the combinations. At this point we should understand the different prognostic groups for the cancers that respond well to the newer agents (lung, renal, melanoma, breast, prostate, colorectal) and have realistic expectations for the expected survival without SABR. Ex: ESRO/ESTRO classification system,Plichta JCO 2023;14:2546, Keynote 024 etc.
Agree and we obviously, as you point out, often lump too many sites together into these approaches. Clearly breast vs. prostate behave differently - recent example is LU002 failure to progress to phase III.
We are beginning to see the limits of targeted therapy and immunotherapy and all the combinations. At this point we should understand the different prognostic groups for the cancers that respond well to the newer agents (lung, renal, melanoma, breast, prostate, colorectal) and have realistic expectations for the expected survival without SABR. Ex: ESRO/ESTRO classification system,Plichta JCO 2023;14:2546, Keynote 024 etc.
Agree and we obviously, as you point out, often lump too many sites together into these approaches. Clearly breast vs. prostate behave differently - recent example is LU002 failure to progress to phase III.